Press coverage about Aradigm Corporation (NASDAQ:ARDM) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aradigm Corporation earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.3726575337248 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Aradigm Corporation (NASDAQ ARDM) opened at 1.42 on Tuesday. Aradigm Corporation has a 52 week low of $0.78 and a 52 week high of $7.19. The company’s market capitalization is $21.08 million. The company’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.51.

Aradigm Corporation (NASDAQ:ARDM) last posted its earnings results on Thursday, August 10th. The company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.37. The business had revenue of $7.68 million during the quarter. Aradigm Corporation had a negative return on equity of 3,432.80% and a negative net margin of 196.65%. On average, equities analysts forecast that Aradigm Corporation will post ($0.74) EPS for the current fiscal year.

Separately, Zacks Investment Research upgraded Aradigm Corporation from a “sell” rating to a “hold” rating in a research note on Monday, June 5th.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Aradigm Corporation (ARDM) Stock Price” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at

Aradigm Corporation Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Insider Buying and Selling by Quarter for Aradigm Corporation (NASDAQ:ARDM)

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.